Built on talent, technology, and trust, Grace is a leading global supplier of specialty chemicals within the Standard Industries family of companies. Our two industry-leading business segments—Catalysts Technologies and Materials Technologies—provide innovative products, technologies, and services that enhance the products and processes of our customers around the world. Through customer-driven innovation, strategic acquisitions, flexible worldwide manufacturing, and the talent of our people, we maintain strong strategic positions and unmatched customer relationships with many of the world’s best companies. Over 80 percent of our sales were in segments where we are #1 or #2. Grace, a Standard Industries company, is committed to delivering value, safely and sustainably, to customers, to shareholders, and to the communities in which we operate.

Centrus Energy is a trusted supplier of nuclear fuel and services for the nuclear power industry. Centrus provides value to its utility customers through the reliability and diversity of its supply sources – helping them meet the growing need for clean, affordable, carbon-free electricity. Since 1998, the Company has provided its utility customers with more than 1,750 reactor years of fuel, which is equivalent to 7 billion tons of coal. With world-class technical and engineering capabilities, Centrus is also advancing the next generation of centrifuge technologies so that America can restore its domestic uranium enrichment capability in the future. Find out more at www.centrusenergy.com.

At Emergent, we develop, manufacture, and deliver protections against public health threats. For more than two decades, we’ve been at work defending people from things we hope will never happen — so that we’re prepared, just in case they ever do. Please note: It has come to our attention that there may be people posing as Emergent recruiters and hiring managers online, offering fraudulent opportunities to job seekers. Emergent will never ask for any financial commitment from a candidate as a pre-employment requirement. Learn more about recruitment fraud and how to protect yourself here: https://bit.ly/recruitment-fraud

For over 30 years, Miltenyi Biotec has been a major provider of products and services that drive biomedical research and boost cell and gene therapy. More than 4,700 employees in 23 countries combine excellence in research with innovative products to create cutting-edge solutions that make cancer and other disease history. Our expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. At Miltenyi Biotec, scientists, engineers, software developers and many other professionals work together to improve human health by providing smarter cellular technology solutions to researchers and clinicians worldwide.

We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 30 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States. We market Qelbree® (viloxazine extended-release) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children ages 6 to 17. Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.

Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s first facility, Calcasieu Pass, commenced producing LNG in January 2022. The company is also constructing or developing an additional 60 MTPA of production capacity in Louisiana to provide clean, affordable energy to the world. The company is developing Carbon Capture and Sequestration (CCS) projects at each of its LNG facilities. For more information, visit https://www.venturegloballng.com

Built on talent, technology, and trust, Grace is a leading global supplier of specialty chemicals within the Standard Industries family of companies. Our two industry-leading business segments—Catalysts Technologies and Materials Technologies—provide innovative products, technologies, and services that enhance the products and processes of our customers around the world. Through customer-driven innovation, strategic acquisitions, flexible worldwide manufacturing, and the talent of our people, we maintain strong strategic positions and unmatched customer relationships with many of the world’s best companies. Over 80 percent of our sales were in segments where we are #1 or #2. Grace, a Standard Industries company, is committed to delivering value, safely and sustainably, to customers, to shareholders, and to the communities in which we operate.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.

OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based tools have enabled the identification of relevant drug targets through system biology approaches. OriGene's vision is to prepare comprehensive, genome-wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. Our flagship product is the cDNA clone collection, a searchable gene bank of over 30,000 human full-length TrueClone cDNA collections and over 25,000 TrueORF cDNA clones. From our TrueORF cDNA clones, we have developed the largest offering of full-length human proteins expressed in mammalian cells, ideal for functional studies. In 2010, OriGene initiated the TrueMAB project to develop mouse monoclonal antibodies against protein antigens to develop protein assays for every human protein. In addition, OriGene offers unique gene expression products such as TissueScan cancer tissue qPCR arrays and tissue biorepository for biomarker discovery and validation OriGene is committed to its mission to be “Your Gene Company”, supplying everything a researcher needs for gene-based research. Visit us at https://www.origene.com

Best Medical International specializes in brachytherapy solutions, and manufactures Best® Iodine-125, Best® Palladium-103, Iridium-192 and Gold-198 seeds, along with HDR accessories, fiducial markers, Best® Brachytherapy Kits and other products. Seeds are available either loose or loaded in cartridges, needles or strands, and are available sterile or non-sterile. Best Medical can make catheters, needles, templates and applicators to meet your special needs. Best Medical International is part of a family of trusted companies now known as TeamBest® with a proven track record of innovation, quality and service in several fields such as external beam radiation therapy, brachytherapy, vascular brachytherapy, dosimetry, health physics, radiation oncology, blood irradiation, imaging and medical particle acceleration.

Ascentage Pharma is a global, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and senesce diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 6855.HK. The Company is dedicated to developing and bringing to market therapies that target each class of molecular pathways regulating apoptosis, or programmed cell death, in a wide range of indications. Headquartered in Suzhou, China, we are a rapidly growing company with offices in three countries. Ascentage Pharma has built a pipeline of seven clinical drug candidates, including novel, highly selective and potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, additional apoptotis inhibitors targeting IAP and MDM2-p53 proteins. The pipeline is balanced by next-generation tyrosine kinase inhibitors (TKIs) aimed at treatment induced resistance mutations. Ascentage Pharma is conducting more than 40 clinical trials in specific regions worldwide.